Opinion
New weight loss drugs raise questions of access, costs
New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health risks posed by obesity. Yet the drugs are so expensive that insurers are often choosing between two bad options: restricting access or raising consumer costs.
What health experts think of the growing Ozempic “microdosing” trend that claims taking very small doses of GLP-1 drugs can ...
Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years according to ...
News Medical on MSN2d
Expanding access to GLP-1 weight-loss drugs could save thousands of livesResearchers estimate that expanding access to weight-loss drugs could save over 50,000 lives annually, reducing obesity rates ...
Not every company is jumping onto the bandwagon and investing into weight loss drugs, however. One of the largest healthcare ...
Sales of GLP-1 weight-loss medications like Wegovy and Zepbound (tirzepatide) have boomed among adults, and with 1 in every 5 U.S. children now obese, the drugs' uptake by adolescents is also ...
2don MSN
Weight-loss supplements are rebranding as “GLP-1 boosters.” They’re nothing like Ozempic. If you had come across the ...
PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...
Met With High Demand, the Dual-Product System is Clinically Shown to Increase GLP-1 by 140% on average to Balance Hunger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback